1-((3S,4S)-4-Amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 6, 2011, Pages 1810-1814

  Andrews, Kim M ^a   Beebe, David A ^a   Benbow, John W ^a   Boyer, David A ^a   Doran, Shawn D ^a   Hui, Yu ^a   Liu, Shenping ^a   McPherson, R Kirk ^a   Neagu, Constantin ^a   Parker, Janice C ^a   Piotrowski, David W ^a   Schneider, Steven R ^a   Treadway, Judith L ^a   Vanvolkenberg, Maria A ^a   Zembrowski, William J ^a  

^a PFIZER INC   (United States)

Author keywords

Dipeptidyl peptidase; DPP 4; Type 2 diabetes

Indexed keywords

3 AMINO 4 (VALEROLACTAM N YL)PYRROLIDINE DERIVATIVE; 3 AMINOPYRROLIDINE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DISTRIBUTION VOLUME; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; LIVER MICROSOME; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACOPHORE; RAT;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; MODELS, MOLECULAR; PIPERIDINES;

RATTUS;

EID: 79952363044     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.01.055     Document Type: Article

References (31)

1. J.S. Flier Cell 116 2004 337
2. P. Hogan, T. Dall, and P. Nikolov Diabetes Care 26 2003 917
3. P.R. Flatt, C.J. Bailey, and B.D. Green Front. Biosci. 13 2008 3648
4. D.J. Drucker Endocrinology 144 2003 5145
5. For comprehensive reviews on DPP-4 inhibitors, see: I. Idris, and R. Donnelly Diabetes Obes. Metab. 9 2007 153
6. T.W. von Geldern, and J.M. Trevillyan Drug Dev. Res. 67 2006 627
7. A.E. Weber J. Med. Chem. 47 2004 4135
8. M.J. Ammirati, K.M. Andrews, D.A. Boyer, A.M. Brodeur, D.E. Danley, S.D. Doran, B. Hulin, S. Liu, R.K. McPherson, S.J. Orena, J.C. Parker, J. Polivkova, X. Qiu, C.B. Soglia, J.L. Treadway, M.A. VanVolkenburg, D.C. Wilder, and D.W. Piotrowski Bioorg. Med. Chem. Lett. 19 2009 1991
9. For alogliptin, see: J. Feng, Z. Zhang, and M.B. Wallace J. Med. Chem. 50 2007 2297
10. For linagliptin, see: Y. Wang, N. Serradell, E. Rosa, and R. Castaner Drugs Future 33 2008 473
11. Some reports have suggested that inhibition of DPP-8/9 is associated with a higher risk of toxicity in animal models, see: G.R. Lankas, B. Leiting, R.S. Roy, G.J. Eiermann, M.G. Beconi, and T. Biftu Diabetes 54 2005 2988
12. However, more recently this assertion has been challenged, see: J.-J. Wu, H.-K. Tang, T.-K. Yeh, C.-M. Chen, H.-S. Shy, Y.-R. Chu, C.-H. Chien, T.-Y. Tsai, Y.-C. Huang, Y.-L. Huang, C.-H. Huang, H.-Y. Tseng, W.-T. Jiaang, Y.-S. Chao, and X. Chen Biochem. Pharmacol. 78 2009 203 We desired to maximize selectivity over DPP-8.
13. D.A. Price, J. Blagg, L. Jones, N. Greene, and T. Wager Expert Opin. Drug Metab. Toxicol. 5 2009 921
14. J.D. Hughes, J. Blagg, D.A. Price, S. Bailey, G.A. DeCrescenzo, R.V. Devraj, E. Ellsworth, Y.M. Fobian, E.M. Gibbs, R.W. Gilles, N. Greene, E. Huang, T. Krieger-Burke, J. Loesel, T. Wager, L. Whiteley, and Y. Zhang Bioorg. Med. Chem. Lett. 18 2008 4872
15. J.W. Benbow, K.A. Andrews, J. Aubrecht, D. Beebe, D. Boyer, S. Doran, M. Homiski, Y. Hui, K. McPherson, J.C. Parker, J. Treadway, M. VanVolkenberg, and W.J. Zembrowski Bioorg. Med. Chem. Lett. 19 2009 2220
16. S.W. Wright, M.J. Ammirati, K.M. Andrews, A.M. Brodeur, D.E. Danley, S.D. Doran, J.S. Lillquist, S. Liu, L.D. McClure, R.K. McPherson, T.V. Olson, S.J. Orena, J.C. Parker, B.N. Rocke, W.C. Soeller, C.B. Soglia, J.T. Treadway, M.A. VanVolkenburg, Z. Zhao, and E.D. Cox Bioorg. Med. Chem. Lett. 17 2007 5638
17. J.W. Corbett, K. Dirico, W. Song, B.P. Boscoe, S.D. Doran, D. Boyer, X. Qiu, M. Ammirati, M.A. VanVolkenburg, R.K. McPherson, J.C. Parker, and E.D. Cox Bioorg. Med. Chem. Lett. 17 2007 6707
18. G.-B. Liang, X. Qian, T. Biftu, S. Singh, Y.-D. Gao, G. Scapin, S. Patel, B. Leiting, R. Patel, J. Wu, X. Zhang, N.A. Thornberry, and A.E. Weber Bioorg. Med. Chem. Lett. 18 2008 3706
19. Benbow, J. W.; Piotrowski, D. W.; Hui, Y. PCT Int. Appl., WO2007148185, 2007.
20. P. Mattei, M. Boehringer, P. Di Giorgio, H. Fischer, M. Hennig, J. Huwyler, B. Koer, B. Kuhn, B.M. Loeffler, A. MacDonald, R. Narquizian, E. Rauber, E. Sebokova, and U. Sprecher Bioorg. Med. Chem. Lett. 20 2010 1109
21. Weingarten, M. D.; Sekanina, K.; Still, W. C. J. Am. Chem. Soc., 1998, 120, 9112, Supplementary data.
22. D. Rejman, P. Kocalka, M. Budesinsky, R. Pohl, and I. Rosenberg Tetrahedron 63 2007 1243
23. C.N. Pace J. Mol. Biol. 226 1992 29
24. The structure has been deposited in the Protein Data Bank with the deposition code 3QBJ.
25. int clearance value of 3.1 mL/min/kg.
26. See: B.L. Mylari, G.J. Withbroe, D.A. Beebe, N.S. Brackett, E.L. Conn, J.B. Coutcher, P.J. Oates, and W.J. Zembrowski Bioorg. Med. Chem. 11 2003 4179 for permeability/absorption benefits by replacement of a pyrimidine with a triazine
27. The rat pharmacodynamic assay is described in: D. Kim, L. Wang, M. Beconi, G.J. Eiermann, M.H. Fisher, H. He, G.J. Hickey, J.E. Kowalchick, B. Leiting, K. Lyons, F. Marsilio, M.E. McCann, R.A. Patel, A. Petrov, G. Scapin, S.B. Patel, R. Sinha Roy, J.K. Wu, M.J. Wyvratt, B.B. Zhang, L. Zhu, N.A. Thornberry, and A.E. Weber J. Med. Chem. 48 2005 141
28. 50 value, and 'I' is the unbound plasma concentration.
29. Differential scanning calorimetry run on diazide intermediate 8 indicated a moderate to high thermal energy release that was within 100 °C of the processing temperature.
30. K.C. Nicolaou, S.A. Snyder, D.A. Longbottom, A.Z. Nalbandian, and X. Huang Chem. Eur. J. 10 2004 5581
31. 2O) afforded the desired acid.